1Greipp R P, Leong T, Bennett J, et al. Plasmablastic morphology-an independent prognostic factor with clinical and laboratory correlates:Eastern Cooperative Oncology Group (ECOG)Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group[J]. Blood,199
2Zojer N, Konigsberg R, Ackermann J, et al. Deletinn of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detectinn by interphase fluorescence in situ hubridization[J]. Blood,2000,95(6)1925-1930.
3Fonseca R, Harrington D ,Oken M, et al. Biologic al and prognostic significance of interphase fluorescence in situ hubridization detection of chromosome 13 abnormalities (△ 13)in multiple myeloma:an Eastern Cooperative Oncology Group Study[J]. Cancer Rea
4Robert K, Morie G, Thomas W, et al. Review of 1027 patients with newly diagnosed multiple myeloma[J]. Mayo Clin Proc, 2003,78:21 -33.
5Knudsen L M, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis[J]. Eur J Haematol,2000,65:175-181.
6Shaheen H, Ghanghroo Ⅰ, Malik Ⅰ. Clinicopathological features and management of Pakistani patients with multiple myeloma[J]. J Pak Med Assoc, 1999, 49(10):233-237.
